trial

Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

NCTId NCT01516424
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 267 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2013-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
267 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-02
Primary completion
2013-02
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
BlonanserinRisperidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor

Investigators

1
Niufan Gu, MDPrincipal Investigator

Sites

16 total
Beijing, ChinaBeijing, ChinaBeijing, ChinaGuangzhou, ChinaBaoding, ChinaHarbin, ChinaXinxiang, ChinaChangsha, ChinaChangsha, ChinaNanjing, ChinaWuxi, ChinaShanghai, China

Linked catalysts

1
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When C — primary completion2013-02

Facts & assertions

4 sourced
Enrollment
267
Phase
PHASE3
Primary Completion Date
2013-02
Status
COMPLETED
relationships
The graph out of here
drug
Blonanserin
drug
Risperidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Niufan Gu, MD
person